StreetInsider.com News Articles

Form 4 ZEVRA THERAPEUTICS, INC. For: Jun 04 Filed by: FAVORITO TAMARA A

Thu, 18 Jun 2026 16:17:00 -0400

si-local-file:///var/storage/secattach/20260618/26666282.html

Form 4 ZEVRA THERAPEUTICS, INC. For: Jun 04 Filed by: FAVORITO TAMARA A

Thu, 18 Jun 2026 16:17:00 -0400

si-local-file:///var/storage/secattach/20260618/26666282.html

Form 4 ZEVRA THERAPEUTICS, INC. For: Jun 04 Filed by: Shih Alvin

Thu, 18 Jun 2026 16:16:00 -0400

si-local-file:///var/storage/secattach/20260618/26666239.html

Form 4 ZEVRA THERAPEUTICS, INC. For: Jun 04 Filed by: Shih Alvin

Thu, 18 Jun 2026 16:16:00 -0400

si-local-file:///var/storage/secattach/20260618/26666239.html

Form 4 ZEVRA THERAPEUTICS, INC. For: Jun 04 Filed by: Anderson Thomas

Thu, 18 Jun 2026 16:16:00 -0400

si-local-file:///var/storage/secattach/20260618/26666244.html

Form 4 ZEVRA THERAPEUTICS, INC. For: Jun 04 Filed by: Anderson Thomas

Thu, 18 Jun 2026 16:16:00 -0400

si-local-file:///var/storage/secattach/20260618/26666244.html

Form 4 ZEVRA THERAPEUTICS, INC. For: Jun 04 Filed by: Calder Douglas W

Thu, 18 Jun 2026 16:16:00 -0400

si-local-file:///var/storage/secattach/20260618/26666252.html

Form 4 ZEVRA THERAPEUTICS, INC. For: Jun 04 Filed by: Calder Douglas W

Thu, 18 Jun 2026 16:16:00 -0400

si-local-file:///var/storage/secattach/20260618/26666252.html

Form 4 ZEVRA THERAPEUTICS, INC. For: Jun 04 Filed by: Watton Corey Michael

Thu, 18 Jun 2026 16:16:00 -0400

si-local-file:///var/storage/secattach/20260618/26666263.html

Form 4 ZEVRA THERAPEUTICS, INC. For: Jun 04 Filed by: Watton Corey Michael

Thu, 18 Jun 2026 16:16:00 -0400

si-local-file:///var/storage/secattach/20260618/26666263.html

Form 4 ZEVRA THERAPEUTICS, INC. For: Jun 04 Filed by: Secor Alicia

Thu, 18 Jun 2026 16:16:00 -0400

si-local-file:///var/storage/secattach/20260618/26666270.html

Form 4 ZEVRA THERAPEUTICS, INC. For: Jun 04 Filed by: Secor Alicia

Thu, 18 Jun 2026 16:16:00 -0400

si-local-file:///var/storage/secattach/20260618/26666270.html

Zevra Therapeutics, Inc. (ZVRA) PT Raised to $35 at Maxim Group

Wed, 10 Jun 2026 14:12:15 -0400

Maxim Group analyst Jason McCarthy raised the price target on Zevra Therapeutics, Inc. (NASDAQ: ZVRA) to $35.00 (from $25.00) while maintaining a Buy rating.

Zevra Therapeutics, Inc. (ZVRA) PT Raised to $29 at Guggenheim

Wed, 10 Jun 2026 06:53:18 -0400

(Updated - June 10, 2026 6:53 AM EDT)

Guggenheim analyst Eddie Hickman raised the price target on Zevra Therapeutics, Inc. (NASDAQ: ZVRA) to $29.00 (from $25.00) while maintaining a Buy rating.

The analyst commented: "This week, ZVRA announced that it submitted U.S. Patent No. 11,707,456 for Orange Book listing on Miplyffa, a synthesis process patent covering the preparation of arimoclomol citrate. This extends the possible exclusivity period to November 2041 from ~2034, where we currently model LOE based on the pending PTE on the '460 composition patent (which expires in 2029 absent extension). While this type of patent (synthesis process) is not

Zevra Therapeutics, Inc. (ZVRA) PT Raised to $29 at Guggenheim

Wed, 10 Jun 2026 06:53:18 -0400

(Updated - June 10, 2026 6:53 AM EDT)

Guggenheim analyst Eddie Hickman raised the price target on Zevra Therapeutics, Inc. (NASDAQ: ZVRA) to $29.00 (from $25.00) while maintaining a Buy rating.

Zevra Therapeutics, Inc. (ZVRA) PT Raised to $27 at BTIG

Tue, 09 Jun 2026 12:51:06 -0400

BTIG analyst Kambiz Yazdi raised the price target on Zevra Therapeutics, Inc. (NASDAQ: ZVRA) to $27.00 (from $23.00) while maintaining a Buy rating.

The analyst comments "Zevra announced submission of U.S. Patent No. 11,707,456 to FDA for Orange Book listing for Miplyffa, with nominal expiry in 2041. U.S. Patent No. 11,707,456 appears to cover a defined arimoclomol citrate composition with specified purity and impurity parameters. If listed, the patent would add another layer to Miplyffa’s IP estate, which already includes Orange Book-listed patents, orphan drug exclusivity to 2031, and a pending patent term extension on U.S. Patent No. 11,045,460 that could

Zevra Therapeutics, Inc. (ZVRA) PT Raised to $27 at BTIG

Tue, 09 Jun 2026 12:51:06 -0400

BTIG analyst Kambiz Yazdi raised the price target on Zevra Therapeutics, Inc. (NASDAQ: ZVRA) to $27.00 (from $23.00) while maintaining a Buy rating.

Zevra Therapeutics, Inc. (ZVRA) PT Raised to $29 at Canaccord

Tue, 09 Jun 2026 06:51:59 -0400

(Updated - June 9, 2026 6:51 AM EDT)

Canaccord analyst Sumant Kulkarni raised the price target on Zevra Therapeutics, Inc. (NASDAQ: ZVRA) to $29.00 (from $24.00) while maintaining a Buy rating.

The analyst commented: "This morning (6/8), ZVRA announced that it has submitted US patent 11,707,456 for Miplyffa (arimoclomol for Niemann-Pick Type C/NPC), which expires on 11/19/41, to be listed in the FDA's Orange Book (OB). In short, this means the potential for Miplyffa to remain a brand in the US goes up by several years vs. prior scenarios. We are therefore moving our generic entry assumption from mid-2031E to the end

Zevra Therapeutics, Inc. (ZVRA) PT Raised to $29 at Canaccord

Tue, 09 Jun 2026 06:51:59 -0400

(Updated - June 9, 2026 6:51 AM EDT)

Canaccord analyst Sumant Kulkarni raised the price target on Zevra Therapeutics, Inc. (NASDAQ: ZVRA) to $29.00 (from $24.00) while maintaining a Buy rating.

H.C. Wainwright Reiterates Buy Rating on Zevra Therapeutics, Inc. (ZVRA)

Tue, 09 Jun 2026 06:44:35 -0400

H.C. Wainwright analyst Brandon Folkes reiterated a Buy rating and $26.00 price target on Zevra Therapeutics, Inc. (NASDAQ: ZVRA).

The analyst commented: "ZVRA’s additional Orange Book patent for MIPLYFFA meaningfully improves the investment setup, in our view, by extending listed patent protection to late 2041 and directly addressing what we believe has been the primary overhang on the stock: visibility into the product’s post-2031 exclusivity runway. We continue to believe the company is executing well on the U.S. MIPLYFFA launch, while the EU opportunity and potential U.S. celiprolol approval remain additional upside drivers not fully reflected in the current valuation. With

Zevra Therapeutics, Inc. (ZVRA) PT Raised to $25 at Citizens

Tue, 09 Jun 2026 05:02:38 -0400

Citizens analyst Jason Butler raised the price target on Zevra Therapeutics, Inc. (NASDAQ: ZVRA) to $25.00 (from $18.00) while maintaining a Market Outperform rating.

The analyst commented, "Expanding Orange Book-listed patent portfolio drive confidence that MIPLYFFA brand exclusivity can extend meaningfully beyond the Orphan Drug Exclusivity period; we reiterate our Market Outperform rating and increase our risk-adjusted, DCF-derived price target on Zevra to $25 from $18. Yesterday, Zevra announced that it has submitted an additional patent to be listed in the Orange Book, providing MIPLYFFA with exclusivity through YE 2041. We increase our price target to reflect this prolonged exclusivity duration

Zevra Therapeutics, Inc. (ZVRA) PT Raised to $25 at Citizens

Tue, 09 Jun 2026 05:02:38 -0400

Citizens analyst Jason Butler raised the price target on Zevra Therapeutics, Inc. (NASDAQ: ZVRA) to $25.00 (from $18.00) while maintaining a Market Outperform rating.

Zevra Therapeutics, Inc. (ZVRA) PT Raised to Street High $34 at Cantor Fitzgerald

Mon, 08 Jun 2026 10:07:55 -0400

Cantor Fitzgerald analyst Kristen Kluska raised the price target on Zevra Therapeutics, Inc. (NASDAQ: ZVRA) to $34.00 (from $24.00) while maintaining a Overweight rating.

Form 8-K ZEVRA THERAPEUTICS, INC. For: Jun 04

Fri, 05 Jun 2026 16:19:00 -0400

si-local-file:///var/storage/secattach/20260605/26611352.html

Form 8-K ZEVRA THERAPEUTICS, INC. For: Jun 04

Fri, 05 Jun 2026 16:19:00 -0400

si-local-file:///var/storage/secattach/20260605/26611352.html